Literature DB >> 11735629

Imatinib: A Viewpoint by Brian J. Druker.

Brian J. Druker1.   

Abstract

Entities:  

Year:  2001        PMID： 11735629     DOI： 10.2165/00003495-200161120-00009

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  4 in total

Review 1.  Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.

Authors:  Ebubekir Dirican; Mustafa Akkiprik; Ayşe Özer
Journal:  Tumour Biol       Date:  2016-02-26

2.  Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.

Authors:  Jamie E Chaft; Geoffrey R Oxnard; Camelia S Sima; Mark G Kris; Vincent A Miller; Gregory J Riely
Journal:  Clin Cancer Res       Date:  2011-08-19       Impact factor: 12.531

Review 3.  Sweet dreams: How mini-invasive surgery tackles obstructive sleep apnea.

Authors:  Sophia Julia Häfner
Journal:  Biomed J       Date:  2019-05-20       Impact factor: 4.910

Review 4.  Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Kathrin M Bernt; Stephen P Hunger
Journal:  Front Oncol       Date:  2014-03-25       Impact factor: 6.244
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.